Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers
Background/Aims Anti- Helicobacter pylori treatment with combinations of omeprazole and amoxicillin is a promising treatment option. The aim of this study was to investigate whether a daily omeprazole dose of 120 mg combined with amoxicillin would cure H. pylori infection at a rate comparable with t...
Gespeichert in:
Veröffentlicht in: | Gastroenterology (New York, N.Y. 1943) N.Y. 1943), 1995-05, Vol.108 (5), p.1412-1417 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1417 |
---|---|
container_issue | 5 |
container_start_page | 1412 |
container_title | Gastroenterology (New York, N.Y. 1943) |
container_volume | 108 |
creator | Bayerdörffer, Ekkehard Miehlke, Stephan Mannes, Gerd A. Sommer, Albrecht Höchter, Wilhelm Weingart, Josef Heldwein, Walter Klann, Hermann Simon, Thomas Schmitt, Wolfgang Bästlein, Elke Eimiller, Albert Hatz, Rudolf Lehn, Norbert Dirschedl, Peter Stolte, Manfred |
description | Background/Aims
Anti-
Helicobacter pylori treatment with combinations of omeprazole and amoxicillin is a promising treatment option. The aim of this study was to investigate whether a daily omeprazole dose of 120 mg combined with amoxicillin would cure
H. pylori infection at a rate comparable with that achieved with “triple therapy.”
Methods
In a double-blind, randomized, controlled, and multicenter trial in Germany, 270 patients with an
H. pylori-associated duodenal ulcer were treated with 40 mg omeprazole three times a day and 750 mg amoxicillin three times a day for the first 14 days (n = 139) followed by 20 mg omeprazole once daily until day 42 or with omeprazole plus 750 mg amoxicillin placebo three times a day for the same time period (n = 131).
Results
Cure rates of
H. pylori infection were 91% in the omeprazole plus amoxicillin group, 0% in the omeprazole plus placebo group, and 89% and 0%, respectively, performing an intention-to-treat analysis. Cure of
H. pylori infection in patients pretreated with omeprazole was only 58% compared with 95% in patients who were not. The cumulative 12-month relapse rates were 11.3% and 44% in the treatment groups and 1.6% in
H. pylori -negative and 49% in
H. pylori-positive patients.
Conclusions
The combination of 120 mg omeprazole daily and 2.25 g amoxicillin daily with its
H. pylori cure rate of around 90% is one of the best tolerated and most effective treatment regimens. |
doi_str_mv | 10.1016/0016-5085(95)90689-4 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77232285</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0016508595906894</els_id><sourcerecordid>77232285</sourcerecordid><originalsourceid>FETCH-LOGICAL-c432t-be95cf8228036f04e458ecf65c00dd01d4e2489dd84e018c268ea9c18c249f473</originalsourceid><addsrcrecordid>eNp9kN-LFSEUxyVattvWf1DgQ0Q9zKaOztWXhdh-7MJCL_Usjh7JcMZJnXa3vz6He7mPgejB8zlfDh-EXlFySQkdPpB2dYJI8U6J94oMUnX8CdpRwWTXeuwp2p2QZ-h5Kb8IIaqX9Byd7_dMDX2_Q_ef0jpG6MYYZodrDibi5HGaYMnmb4qATfs3U3oINsQG4ZqwXTPgG4jBptHYChkvjzHlgMPswdaQ5lbhxdQAcy34PtSf2K3JwdzS12ghlxfozJtY4OXxvUA_vnz-fn3T3X37env98a6zvGe1G0EJ6yVjkvSDJxy4kGD9ICwhzhHqODAulXOSA6HSskGCUXaruPJ831-gt4fcJaffK5Sqp1AsxGhmSGvRTUTf0kUD-QG0OZWSweslh8nkR02J3nzrTabeZGrVzuZb8zb2-pi_jhO409BRcOu_OfZNsSb6bGYbygnrBWOUbDFXBwyaiz8Bsi62ybPgQm5GtUvh_3v8A8LknaQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77232285</pqid></control><display><type>article</type><title>Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>Alma/SFX Local Collection</source><creator>Bayerdörffer, Ekkehard ; Miehlke, Stephan ; Mannes, Gerd A. ; Sommer, Albrecht ; Höchter, Wilhelm ; Weingart, Josef ; Heldwein, Walter ; Klann, Hermann ; Simon, Thomas ; Schmitt, Wolfgang ; Bästlein, Elke ; Eimiller, Albert ; Hatz, Rudolf ; Lehn, Norbert ; Dirschedl, Peter ; Stolte, Manfred</creator><creatorcontrib>Bayerdörffer, Ekkehard ; Miehlke, Stephan ; Mannes, Gerd A. ; Sommer, Albrecht ; Höchter, Wilhelm ; Weingart, Josef ; Heldwein, Walter ; Klann, Hermann ; Simon, Thomas ; Schmitt, Wolfgang ; Bästlein, Elke ; Eimiller, Albert ; Hatz, Rudolf ; Lehn, Norbert ; Dirschedl, Peter ; Stolte, Manfred</creatorcontrib><description>Background/Aims
Anti-
Helicobacter pylori treatment with combinations of omeprazole and amoxicillin is a promising treatment option. The aim of this study was to investigate whether a daily omeprazole dose of 120 mg combined with amoxicillin would cure
H. pylori infection at a rate comparable with that achieved with “triple therapy.”
Methods
In a double-blind, randomized, controlled, and multicenter trial in Germany, 270 patients with an
H. pylori-associated duodenal ulcer were treated with 40 mg omeprazole three times a day and 750 mg amoxicillin three times a day for the first 14 days (n = 139) followed by 20 mg omeprazole once daily until day 42 or with omeprazole plus 750 mg amoxicillin placebo three times a day for the same time period (n = 131).
Results
Cure rates of
H. pylori infection were 91% in the omeprazole plus amoxicillin group, 0% in the omeprazole plus placebo group, and 89% and 0%, respectively, performing an intention-to-treat analysis. Cure of
H. pylori infection in patients pretreated with omeprazole was only 58% compared with 95% in patients who were not. The cumulative 12-month relapse rates were 11.3% and 44% in the treatment groups and 1.6% in
H. pylori -negative and 49% in
H. pylori-positive patients.
Conclusions
The combination of 120 mg omeprazole daily and 2.25 g amoxicillin daily with its
H. pylori cure rate of around 90% is one of the best tolerated and most effective treatment regimens.</description><identifier>ISSN: 0016-5085</identifier><identifier>EISSN: 1528-0012</identifier><identifier>DOI: 10.1016/0016-5085(95)90689-4</identifier><identifier>PMID: 7729633</identifier><identifier>CODEN: GASTAB</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adolescent ; Adult ; Aged ; Amoxicillin - administration & dosage ; Biological and medical sciences ; Double-Blind Method ; Drug Therapy, Combination ; Duodenal Ulcer - drug therapy ; Duodenal Ulcer - etiology ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Germany ; Helicobacter Infections - complications ; Helicobacter Infections - drug therapy ; Helicobacter pylori ; Humans ; Male ; Medical sciences ; Middle Aged ; Omeprazole - administration & dosage ; Other diseases. Semiology ; Recurrence ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><ispartof>Gastroenterology (New York, N.Y. 1943), 1995-05, Vol.108 (5), p.1412-1417</ispartof><rights>1995</rights><rights>1995 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c432t-be95cf8228036f04e458ecf65c00dd01d4e2489dd84e018c268ea9c18c249f473</citedby><cites>FETCH-LOGICAL-c432t-be95cf8228036f04e458ecf65c00dd01d4e2489dd84e018c268ea9c18c249f473</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0016-5085(95)90689-4$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3522104$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7729633$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bayerdörffer, Ekkehard</creatorcontrib><creatorcontrib>Miehlke, Stephan</creatorcontrib><creatorcontrib>Mannes, Gerd A.</creatorcontrib><creatorcontrib>Sommer, Albrecht</creatorcontrib><creatorcontrib>Höchter, Wilhelm</creatorcontrib><creatorcontrib>Weingart, Josef</creatorcontrib><creatorcontrib>Heldwein, Walter</creatorcontrib><creatorcontrib>Klann, Hermann</creatorcontrib><creatorcontrib>Simon, Thomas</creatorcontrib><creatorcontrib>Schmitt, Wolfgang</creatorcontrib><creatorcontrib>Bästlein, Elke</creatorcontrib><creatorcontrib>Eimiller, Albert</creatorcontrib><creatorcontrib>Hatz, Rudolf</creatorcontrib><creatorcontrib>Lehn, Norbert</creatorcontrib><creatorcontrib>Dirschedl, Peter</creatorcontrib><creatorcontrib>Stolte, Manfred</creatorcontrib><title>Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers</title><title>Gastroenterology (New York, N.Y. 1943)</title><addtitle>Gastroenterology</addtitle><description>Background/Aims
Anti-
Helicobacter pylori treatment with combinations of omeprazole and amoxicillin is a promising treatment option. The aim of this study was to investigate whether a daily omeprazole dose of 120 mg combined with amoxicillin would cure
H. pylori infection at a rate comparable with that achieved with “triple therapy.”
Methods
In a double-blind, randomized, controlled, and multicenter trial in Germany, 270 patients with an
H. pylori-associated duodenal ulcer were treated with 40 mg omeprazole three times a day and 750 mg amoxicillin three times a day for the first 14 days (n = 139) followed by 20 mg omeprazole once daily until day 42 or with omeprazole plus 750 mg amoxicillin placebo three times a day for the same time period (n = 131).
Results
Cure rates of
H. pylori infection were 91% in the omeprazole plus amoxicillin group, 0% in the omeprazole plus placebo group, and 89% and 0%, respectively, performing an intention-to-treat analysis. Cure of
H. pylori infection in patients pretreated with omeprazole was only 58% compared with 95% in patients who were not. The cumulative 12-month relapse rates were 11.3% and 44% in the treatment groups and 1.6% in
H. pylori -negative and 49% in
H. pylori-positive patients.
Conclusions
The combination of 120 mg omeprazole daily and 2.25 g amoxicillin daily with its
H. pylori cure rate of around 90% is one of the best tolerated and most effective treatment regimens.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Amoxicillin - administration & dosage</subject><subject>Biological and medical sciences</subject><subject>Double-Blind Method</subject><subject>Drug Therapy, Combination</subject><subject>Duodenal Ulcer - drug therapy</subject><subject>Duodenal Ulcer - etiology</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Germany</subject><subject>Helicobacter Infections - complications</subject><subject>Helicobacter Infections - drug therapy</subject><subject>Helicobacter pylori</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Omeprazole - administration & dosage</subject><subject>Other diseases. Semiology</subject><subject>Recurrence</subject><subject>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><issn>0016-5085</issn><issn>1528-0012</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kN-LFSEUxyVattvWf1DgQ0Q9zKaOztWXhdh-7MJCL_Usjh7JcMZJnXa3vz6He7mPgejB8zlfDh-EXlFySQkdPpB2dYJI8U6J94oMUnX8CdpRwWTXeuwp2p2QZ-h5Kb8IIaqX9Byd7_dMDX2_Q_ef0jpG6MYYZodrDibi5HGaYMnmb4qATfs3U3oINsQG4ZqwXTPgG4jBptHYChkvjzHlgMPswdaQ5lbhxdQAcy34PtSf2K3JwdzS12ghlxfozJtY4OXxvUA_vnz-fn3T3X37env98a6zvGe1G0EJ6yVjkvSDJxy4kGD9ICwhzhHqODAulXOSA6HSskGCUXaruPJ831-gt4fcJaffK5Sqp1AsxGhmSGvRTUTf0kUD-QG0OZWSweslh8nkR02J3nzrTabeZGrVzuZb8zb2-pi_jhO409BRcOu_OfZNsSb6bGYbygnrBWOUbDFXBwyaiz8Bsi62ybPgQm5GtUvh_3v8A8LknaQ</recordid><startdate>19950501</startdate><enddate>19950501</enddate><creator>Bayerdörffer, Ekkehard</creator><creator>Miehlke, Stephan</creator><creator>Mannes, Gerd A.</creator><creator>Sommer, Albrecht</creator><creator>Höchter, Wilhelm</creator><creator>Weingart, Josef</creator><creator>Heldwein, Walter</creator><creator>Klann, Hermann</creator><creator>Simon, Thomas</creator><creator>Schmitt, Wolfgang</creator><creator>Bästlein, Elke</creator><creator>Eimiller, Albert</creator><creator>Hatz, Rudolf</creator><creator>Lehn, Norbert</creator><creator>Dirschedl, Peter</creator><creator>Stolte, Manfred</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19950501</creationdate><title>Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers</title><author>Bayerdörffer, Ekkehard ; Miehlke, Stephan ; Mannes, Gerd A. ; Sommer, Albrecht ; Höchter, Wilhelm ; Weingart, Josef ; Heldwein, Walter ; Klann, Hermann ; Simon, Thomas ; Schmitt, Wolfgang ; Bästlein, Elke ; Eimiller, Albert ; Hatz, Rudolf ; Lehn, Norbert ; Dirschedl, Peter ; Stolte, Manfred</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c432t-be95cf8228036f04e458ecf65c00dd01d4e2489dd84e018c268ea9c18c249f473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Amoxicillin - administration & dosage</topic><topic>Biological and medical sciences</topic><topic>Double-Blind Method</topic><topic>Drug Therapy, Combination</topic><topic>Duodenal Ulcer - drug therapy</topic><topic>Duodenal Ulcer - etiology</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Germany</topic><topic>Helicobacter Infections - complications</topic><topic>Helicobacter Infections - drug therapy</topic><topic>Helicobacter pylori</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Omeprazole - administration & dosage</topic><topic>Other diseases. Semiology</topic><topic>Recurrence</topic><topic>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bayerdörffer, Ekkehard</creatorcontrib><creatorcontrib>Miehlke, Stephan</creatorcontrib><creatorcontrib>Mannes, Gerd A.</creatorcontrib><creatorcontrib>Sommer, Albrecht</creatorcontrib><creatorcontrib>Höchter, Wilhelm</creatorcontrib><creatorcontrib>Weingart, Josef</creatorcontrib><creatorcontrib>Heldwein, Walter</creatorcontrib><creatorcontrib>Klann, Hermann</creatorcontrib><creatorcontrib>Simon, Thomas</creatorcontrib><creatorcontrib>Schmitt, Wolfgang</creatorcontrib><creatorcontrib>Bästlein, Elke</creatorcontrib><creatorcontrib>Eimiller, Albert</creatorcontrib><creatorcontrib>Hatz, Rudolf</creatorcontrib><creatorcontrib>Lehn, Norbert</creatorcontrib><creatorcontrib>Dirschedl, Peter</creatorcontrib><creatorcontrib>Stolte, Manfred</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gastroenterology (New York, N.Y. 1943)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bayerdörffer, Ekkehard</au><au>Miehlke, Stephan</au><au>Mannes, Gerd A.</au><au>Sommer, Albrecht</au><au>Höchter, Wilhelm</au><au>Weingart, Josef</au><au>Heldwein, Walter</au><au>Klann, Hermann</au><au>Simon, Thomas</au><au>Schmitt, Wolfgang</au><au>Bästlein, Elke</au><au>Eimiller, Albert</au><au>Hatz, Rudolf</au><au>Lehn, Norbert</au><au>Dirschedl, Peter</au><au>Stolte, Manfred</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers</atitle><jtitle>Gastroenterology (New York, N.Y. 1943)</jtitle><addtitle>Gastroenterology</addtitle><date>1995-05-01</date><risdate>1995</risdate><volume>108</volume><issue>5</issue><spage>1412</spage><epage>1417</epage><pages>1412-1417</pages><issn>0016-5085</issn><eissn>1528-0012</eissn><coden>GASTAB</coden><abstract>Background/Aims
Anti-
Helicobacter pylori treatment with combinations of omeprazole and amoxicillin is a promising treatment option. The aim of this study was to investigate whether a daily omeprazole dose of 120 mg combined with amoxicillin would cure
H. pylori infection at a rate comparable with that achieved with “triple therapy.”
Methods
In a double-blind, randomized, controlled, and multicenter trial in Germany, 270 patients with an
H. pylori-associated duodenal ulcer were treated with 40 mg omeprazole three times a day and 750 mg amoxicillin three times a day for the first 14 days (n = 139) followed by 20 mg omeprazole once daily until day 42 or with omeprazole plus 750 mg amoxicillin placebo three times a day for the same time period (n = 131).
Results
Cure rates of
H. pylori infection were 91% in the omeprazole plus amoxicillin group, 0% in the omeprazole plus placebo group, and 89% and 0%, respectively, performing an intention-to-treat analysis. Cure of
H. pylori infection in patients pretreated with omeprazole was only 58% compared with 95% in patients who were not. The cumulative 12-month relapse rates were 11.3% and 44% in the treatment groups and 1.6% in
H. pylori -negative and 49% in
H. pylori-positive patients.
Conclusions
The combination of 120 mg omeprazole daily and 2.25 g amoxicillin daily with its
H. pylori cure rate of around 90% is one of the best tolerated and most effective treatment regimens.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>7729633</pmid><doi>10.1016/0016-5085(95)90689-4</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0016-5085 |
ispartof | Gastroenterology (New York, N.Y. 1943), 1995-05, Vol.108 (5), p.1412-1417 |
issn | 0016-5085 1528-0012 |
language | eng |
recordid | cdi_proquest_miscellaneous_77232285 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete; Alma/SFX Local Collection |
subjects | Adolescent Adult Aged Amoxicillin - administration & dosage Biological and medical sciences Double-Blind Method Drug Therapy, Combination Duodenal Ulcer - drug therapy Duodenal Ulcer - etiology Female Gastroenterology. Liver. Pancreas. Abdomen Germany Helicobacter Infections - complications Helicobacter Infections - drug therapy Helicobacter pylori Humans Male Medical sciences Middle Aged Omeprazole - administration & dosage Other diseases. Semiology Recurrence Stomach. Duodenum. Small intestine. Colon. Rectum. Anus |
title | Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T03%3A12%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Double-blind%20trial%20of%20omeprazole%20and%20amoxicillin%20to%20cure%20Helicobacter%20pylori%20infection%20in%20patients%20with%20duodenal%20ulcers&rft.jtitle=Gastroenterology%20(New%20York,%20N.Y.%201943)&rft.au=Bayerd%C3%B6rffer,%20Ekkehard&rft.date=1995-05-01&rft.volume=108&rft.issue=5&rft.spage=1412&rft.epage=1417&rft.pages=1412-1417&rft.issn=0016-5085&rft.eissn=1528-0012&rft.coden=GASTAB&rft_id=info:doi/10.1016/0016-5085(95)90689-4&rft_dat=%3Cproquest_cross%3E77232285%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77232285&rft_id=info:pmid/7729633&rft_els_id=0016508595906894&rfr_iscdi=true |